Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1654 1658 1674 1675
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18297353 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PROLIFERATIVE DISEASES AND DISORDERS | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17998137 | IMMUNOMODULATORS | Non-Final OA | Bristol-Myers Squibb Company |
| 18000644 | Compounds and Methods for Treating, Ameliorating, or Preventing Herpes Ocular Keratitis | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18954145 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Non-Final OA | Acceleron Pharma Inc. |
| 18011261 | ACTRII PROTEINS FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION (PAH) | Final Rejection | Acceleron Pharma Inc. |
| 18015906 | NOVEL PEPTIDE TAG | Final Rejection | Technische Universität München |
| 18655057 | DIPEPTIDOMIMETICS AS INHIBITORS OF HUMAN IMMUNOPROTEASOMES | Non-Final OA | CORNELL UNIVERSITY |
| 17905660 | Lipid conjugated peptide inhibitors of PICK1 | Non-Final OA | University of Copenhagen |
| 18515654 | VIRAL VECTOR FOR THE TARGETED TRANSFER OF GENES IN THE BRAIN AND SPINAL CORD | Final Rejection | Boehringer Ingelheim International GmbH |
| 18404263 | AROMATIC-CATIONIC PEPTIDES AND USES OF SAME | Final Rejection | Stealth BioTherapeutics Inc. |
| 18494682 | MEANS AND METHODS FOR THE TREATMENT OF ANGIOGENESIS-, FIBROSIS- AND CANCER-RELATED DISEASES WITH PROTEIN OLIGOMERS COMPRISING NC-1-FC | Non-Final OA | Heidelberg Biotech GmbH |
| 18370922 | COMPOSITIONS AND METHODS FOR REDUCING GAMMA-GLUTAMYLTRANSFERASE LEVELS | Non-Final OA | Lile Method Research, LLC |
| 18330748 | PEPTIDES FOR INCREASING DRUG DELIVERY TO CANCER | Final Rejection | Chapman University |
| 18546794 | COMPOUNDS FOR USE IN THE TREATMENT OF AN ENVELOPED VIRUS INFECTION | Non-Final OA | PHARMA HOLDINGS AS |
| 18039333 | COMPOSITION FOR SUPPRESSION OF INFLAMMATORY DISEASES COMPRISING BIOCOMPATIBLE POLYPEPTIDE TO WHICH FUNCTIONAL PEPTIDE IS CONJUGATED | Non-Final OA | BIOVIT CO., LTD. |
| 18139810 | THERAPEUTIC PEPTIDE COMPOSITION AND METHODS OF TREATMENT | Final Rejection | RAJASEKARAN, NARENDIRAN, DR. |
| 17056231 | USE OF NOD2 AGONIST FOR THE TREATMENT, PROPHYLAXIS AND/OR DELAY OF THE ONSET OF MULTIPLE SCLEROSIS AND ALZHEIMER'S DISEASE | Final Rejection | UNIVERSITE LAVAL |
| 17996228 | LARAZOTIDE DERIVATIVES COMPRISING D-AMINO ACIDS | Non-Final OA | Interlude Biopharma Co. |
| 17802338 | USE OF PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE (PAM) FOR THERAPEUTIC PURPOSE | Final Rejection | PAM THERAGNOSITICS GMBH |
| 17045535 | PHARMACEUTICAL COMPOSITIONS FOR THE TRANSMUCOSAL DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS | Final Rejection | CYPRUMED GMBH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy